0 items USD 0.00Search
Your search for "hjresearch global hemophilia b recombinant factor replacement therapy industry market research" gave back 819845 results.
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood...
Catalog:
MRRPB5
June 2023
Price: USD 4,900.00
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood...
Catalog:
MRRPB5
April 2023
Price: USD 2,900.00
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in...
Catalog:
MRRPB5
October 2023
Price: USD 2,900.00
Hemophilia is a hereditary genetic disorder which impairs body’s ability to control coagulation or blood clotting. In this disease, clotting factors...
Catalog:
MRRPB5
November 2023
Price: USD 3,350.00
The global Recombinant Plasma Protein Therapeutics market size was valued at US$ 90 million in 2023. With growing demand in downstream market, the...
Catalog:
LPI
March 2024
Price: USD 3,660.00
Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant...
Catalog:
MRRPB5
April 2023
Price: USD 2,900.00
RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A. The global Plasma-derived Factor VIII market...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
The global Recombinant Human Coagulation Factor VIII market size was valued at US$ million in 2022. With growing demand in downstream market, the...
Catalog:
LPI
December 2023
Price: USD 3,660.00
Hemophilia is a hereditary genetic disorder which impairs body’s ability to control coagulation or blood clotting. In this disease, clotting factors...
Catalog:
MRRPB5
July 2023
Price: USD 4,900.00
Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant...
Catalog:
MRRPB5
August 2023
Price: USD 4,900.00
The global Plasma-derived Factor VIII market size was valued at US$ 8570.4 million in 2023. With growing demand in downstream market, the Plasma-...
Catalog:
LPI
March 2024
Price: USD 3,660.00
RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A. The global Plasma-derived Factor VIII market...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. The...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
